Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) reported Q4 EPS of $0.17, $0.18 worse than the analyst estimate of $0.35. Revenue for the quarter came in at $202.13 million versus the consensus estimate of $199.61 million.

For earnings history and earnings-related data on Kiniksa Pharmaceuticals, Ltd. (KNSA) click here.